Abstract 3508: Zoledronate induce expansion of glypican-3 (GPC3) peptide specific cytotoxic T lLymphocytes sufficient for adoptive cancer immunotherapy
Toshiaki Yoshikawa(Aichi Cancer Center), Tetsuya Nakatsura(Unknown), Masashi Takahara, Mai Tomiyama, Daisuke Nobuoka(Fukuyama City Hospital), Noriko Sakemura(National Cancer Center Hospital East), Ryuji Maekawa, Ayumi Kuroda(Hyogo Medical University), Yu Sawada(Shizuoka Cancer Center), Hirofumi Shirakawa(Shizuoka Cancer Center), Mie Nieda(The University of Queensland)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
|British Journal of Cancer|2011|240
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104